$0.53
6.20% today
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US7530181004
Symbol
RANI

Rani Therapeutics Holdings Inc - Ordinary Shares Class A Stock price

$0.53
-0.17 23.97% 1M
-1.16 68.58% 6M
-0.84 61.24% YTD
-1.84 77.61% 1Y
-10.79 95.31% 3Y
-10.47 95.17% 5Y
-10.47 95.17% 10Y
-10.47 95.17% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.03 6.20%
ISIN
US7530181004
Symbol
RANI
Industry

Key metrics

Basic
Market capitalization
$33.8m
Enterprise Value
$40.8m
Net debt
$7.0m
Cash
$10.2m
Shares outstanding
63.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
28.2 | 182.6
EV/Sales
34.0 | 220.5
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
5.4%
Return on Equity
-1,506.9%
ROCE
1,324.6%
ROIC
-
Debt/Equity
-3.1
Financials (TTM | estimate)
Revenue
$1.2m | $185.0k
EBITDA
$-48.3m | $-53.9m
EBIT
$-49.3m | $-50.5m
Net Income
$-29.7m | $-41.5m
Free Cash Flow
$-31.3m
Growth (TTM | estimate)
Revenue
- | -82.0%
EBITDA
15.2% | -10.9%
EBIT
14.8% | -1.8%
Net Income
2.9% | -38.2%
Free Cash Flow
32.0%
Margin (TTM | estimate)
Gross
-
EBITDA
-4,021.6% | -29,118.7%
EBIT
-4,106.3%
Net
-2,473.8% | -22,425.9%
Free Cash Flow
-2,604.5%
More
EPS
$-0.8
FCF per Share
$-0.5
Short interest
23.9%
Employees
140
Rev per Employee
$10.0k
Show more

Is Rani Therapeutics Holdings Inc - Ordinary Shares Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Rani Therapeutics Holdings Inc - Ordinary Shares Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Rani Therapeutics Holdings Inc - Ordinary Shares Class A forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Rani Therapeutics Holdings Inc - Ordinary Shares Class A forecast:

Buy
89%
Hold
11%

Financial data from Rani Therapeutics Holdings Inc - Ordinary Shares Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
1.20 1.20
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 22 22
14% 14%
1,808%
- Research and Development Expense 25 25
23% 23%
2,088%
-48 -48
15% 15%
-4,022%
- Depreciation and Amortization 1.02 1.02
7% 7%
85%
EBIT (Operating Income) EBIT -49 -49
15% 15%
-4,106%
Net Profit -30 -30
3% 3%
-2,474%

In millions USD.

Don't miss a Thing! We will send you all news about Rani Therapeutics Holdings Inc - Ordinary Shares Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rani Therapeutics Holdings Inc - Ordinary Shares Class A Stock News

Positive
The Motley Fool
5 days ago
Rani Therapeutics (RANI -3.04%), a biotech company developing oral biologic drug delivery technology, released its earnings for the second quarter of fiscal 2025 on August 7, 2025. Marking an improvement from the prior year period's $(0.26) GAAP result.
Neutral
GlobeNewsWire
5 days ago
– Announced strategic research collaboration with Chugai for two undisclosed molecules – – Presented preclinical data demonstrating bioequivalence of novel, bispecific GLP-1/GLP-2 receptor agonist delivered orally via RaniPill (RT-114) compared to subcutaneous delivery at ENDO 2025 – – Phase 1 study for RT-114 for the treatment of obesity expected to initiate in the second half of 2025 – – Anno...
Neutral
GlobeNewsWire
28 days ago
SAN JOSE, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 4,354,000 shares of Rani Therap...
More Rani Therapeutics Holdings Inc - Ordinary Shares Class A News

Company Profile

Rani Therapeutics Holdings, Inc. operates as a clinical stage bio-therapeutics company providing technologies to enable the development of orally administered biologics. It offers RaniPill capsule, an orally ingestible pill for the administration of a broad range of biologics. The company was founded by Mir Imran on April 6, 2021 and is headquartered in San Jose, CA.

Head office United States
CEO Talat Imran
Employees 140
Founded 2012
Website www.ranitherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today